GLP-1 Receptor Agonists and Your Heart: What the Evidence Shows About Cardiovascular Protection

Patients walk into my Encinitas office asking about Ozempic, Wegovy, Mounjaro, and Zepbound because a friend lost forty pounds or because the commercial keeps running. What most of them haven’t heard is that the same shots cut heart attacks, strokes, and deaths from heart disease in several large studies, in people with diabetes and in people without it, in people with known heart disease and in people at risk for it. For the right patient, starting one is a heart decision on its own, separate from the scale and separate from blood sugar. Here’s what the studies actually show, who gains the most, and how I decide in clinic.

What Are GLP-1 Receptor Agonists?

GLP-1 receptor agonists are lab-made copies of a hormone your gut releases after you eat. They do what the natural hormone does, telling your pancreas to release insulin, telling your liver to stop dumping sugar into your blood, slowing how fast food leaves your stomach, and telling your brain you’ve had enough. The difference is that they last about a week instead of a few minutes.

The natural hormone is called glucagon-like peptide-1, which is where GLP-1 comes from. Your gut squirts it out when food arrives, and it does four things at once. It nudges the pancreas to release insulin only when your blood sugar is actually up, which is why these drugs rarely bottom your sugar out the way insulin can. The liver gets told to quit making extra sugar. The stomach slows down so food sits longer. And it sends a fullness signal to the brain, which is the part patients feel most.

Then your body breaks it down within minutes. The drugs are built to hit the same switch and survive that breakdown, which is why one shot covers a whole week.

The drugs in this family with real heart data are semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro, Zepbound). Tirzepatide flips a second gut-hormone switch in addition to the GLP-1 one, and that second switch buys somewhat more weight loss and somewhat better blood sugar. The heart evidence runs deepest for semaglutide, liraglutide, and dulaglutide, because those three have finished dedicated heart-outcome studies. Tirzepatide’s heart data is arriving now, first in heart failure and, over the next few years, in clogged-artery disease.

How Do GLP-1 Drugs Protect the Heart?

No single effect explains the benefit. These drugs take weight off, especially the deep belly fat that wraps around your organs, calm down body-wide inflammation, help the lining of your arteries work better, drop blood pressure a few points, and nudge cholesterol and triglycerides down. Stack all of that together and you get more protection than any one piece would predict.

GLP-1 Cardiovascular Outcomes Trials

Start with the weight, since that’s the part you can see in the mirror. It pulls a lot of other things along with it. On the higher doses of semaglutide most people lose somewhere around 9 to 15% of their body weight, and on tirzepatide it runs 15 to 22%. Even the smaller drops on liraglutide and dulaglutide move blood pressure, cholesterol, blood sugar, sleep apnea, and belly fat in the right direction. Each of those protects the heart on its own. Together they account for a good share of what the studies found.

Blood sugar control is real but smaller than people assume. In someone with type 2 diabetes, the A1c (a blood test that reflects your average sugar over about three months) falls one to two points on these drugs. Better sugar control helps the heart a little. It doesn’t come close to explaining the size of what the studies showed. SELECT proved that directly, because the people in it didn’t have diabetes at all, and their hearts still did better.

So what accounts for the rest? Most likely the arteries themselves. GLP-1 switches sit on the cells lining your blood vessels and on immune cells, and turning them on seems to help those vessels relax and open the way they should, while quieting inflammation throughout the body. A blood test called high-sensitivity CRP, which measures that inflammation, drops 37 to 43% on semaglutide, about what a statin does. We already know from other research that calming inflammation by itself prevents heart attacks, so this is a believable piece of the puzzle.

Blood pressure comes down 2 to 6 points on the top number, LDL and triglycerides slip a little, and the fat packed around the organs, including the layer that sits directly on the heart and that we can measure on a CT scan, shrinks. None of that is dramatic alone. Piled on the weight, sugar, and inflammation changes, it adds up.

What Did the GLP-1 Outcomes Trials Show?

Every major heart study in this drug family found 12 to 26% fewer heart attacks, strokes, and cardiac deaths compared with placebo. SELECT then extended that benefit to people who carry extra weight and don’t have diabetes, which is what turned these into heart drugs.

LEADER put 9,340 people with type 2 diabetes and either known heart disease or high risk on liraglutide or a placebo shot. Over about four years, liraglutide cut the combined count of cardiac death, nonfatal heart attack, and nonfatal stroke by 13%. Deaths from heart disease alone fell 22%, and deaths from any cause fell 15%. That was the first hint these drugs were doing something beyond blood sugar.

SUSTAIN-6 tested weekly semaglutide in a similar group and, over about two years, cut the same combined count by 26%, driven mostly by 39% fewer strokes. The curves separated inside the first year. That was faster than anyone expected.

REWIND studied dulaglutide in a wider group, including many people who’d never had a heart attack or stroke. Over five and a half years it cut events by 12%, with a strong effect on stroke in particular. REWIND stretched the evidence from “diabetes plus known heart disease” out to “diabetes plus high risk.”

SELECT is the one that changed my practice. It enrolled 17,604 people who had known heart disease and a BMI of 27 or higher, and none of them had diabetes. Semaglutide 2.4 mg weekly cut cardiac death, heart attack, and stroke by 20% over a little more than three years. A weight-loss drug had never before been shown to prevent actual heart attacks in people without diabetes. It’s the reason cardiologists now treat excess weight as something we can act on, the same way we act on cholesterol.

A 2025 review pooling 99,599 people across 21 studies landed on a steady 12 to 14% reduction across the whole drug family, holding up whether or not people had diabetes, kidney disease, or heart failure. Put another way, in higher-risk patients you’d need to treat roughly 50 to 75 people for three years to prevent one heart attack, stroke, or cardiac death. That’s in the same range as modern cholesterol drugs, which is a number I find useful to say out loud in the room, because “20% reduction” sounds enormous and “one in sixty” sounds small, and both are true.

Do GLP-1 Drugs Also Protect the Kidneys?

Yes. In the FLOW study, people with type 2 diabetes and chronic kidney disease who took semaglutide had 24% fewer kidney failures and cardiac deaths. The kidney protection looks a lot like what we see with SGLT2 inhibitors, and the two drug types are now often prescribed together.

LEADER, SUSTAIN-6, and REWIND all slowed the leak of protein into the urine, which is one of the earliest signs that diabetes is damaging the kidney filters. FLOW was the study built to answer the kidney question head-on. It randomized 3,533 people with type 2 diabetes and chronic kidney disease to semaglutide or placebo, and it was stopped early because the answer was already clear. Kidney failure, major loss of kidney function, and kidney or heart death dropped 24% as a group. Deaths from heart disease fell 29%.

For someone with both diabetes and kidney disease, GLP-1 drugs now sit next to SGLT2 inhibitors as kidney protectors. They work by different routes. SGLT2 inhibitors take pressure off the kidney’s filters directly. GLP-1 drugs seem to help through weight, blood pressure, and inflammation, and possibly by protecting the filter cells themselves. Because the routes don’t overlap, you don’t have to choose. Using both is now standard for people with diabetes plus heart or kidney disease.

Who Benefits Most From GLP-1 Receptor Agonists?

The biggest gains go to people who already have artery disease along with extra weight, people with type 2 diabetes at high heart risk, people with stiff-heart failure and obesity, and people with diabetes plus chronic kidney disease. All four groups now have guideline support for these drugs as heart protection in their own right.

I sort candidates into four tiers.

Tier 1 is type 2 diabetes plus artery disease you can point to, meaning a prior heart attack or stroke, blockages seen on a heart catheterization, or leg artery disease causing symptoms. For these patients a GLP-1 drug and an SGLT2 inhibitor now go on alongside metformin no matter what the A1c says. The 2025 American Diabetes Association standards and the cardiology consensus documents both say so.

Tier 2 is type 2 diabetes with high risk but no event yet, which is the group REWIND covered. The percentage benefit looks about the same, and the real-world payoff is smaller simply because these patients start from lower risk.

Tier 3 is the SELECT group, meaning known heart disease and a BMI of 27 or above without diabetes. That’s a lot of people. I talk about semaglutide 2.4 mg here the way I talk about adding ezetimibe, a PCSK9 inhibitor, or inclisiran, as one more heart drug with a heart reason behind it.

Tier 4 is diabetes plus chronic kidney disease. After FLOW, most guidelines no longer treat this as optional, and I don’t either.

Everyone else is a case-by-case conversation.

Heart failure needs a more careful answer. In stiff-heart failure with obesity, where the heart squeezes fine but can’t relax and fill properly, semaglutide improved symptoms, weight, walking distance, and the blood markers of inflammation and heart strain across two studies. Pooling four studies together, semaglutide cut cardiac death and worsening heart failure by 31% in this group. The SUMMIT study found the same kind of benefit with tirzepatide. Both are reasonable choices here. In weak-pump heart failure, where the squeeze itself is impaired, the picture is murkier and one small liraglutide study raised the possibility of harm. My practice is to steer clear of these drugs when the pump is severely weakened unless there’s a compelling separate reason to use one, and I’ve made exceptions maybe twice.

What Are the Side Effects of GLP-1 Receptor Agonists?

Stomach complaints lead the list. Nausea, feeling full after a few bites, constipation, and occasional vomiting are the usual ones. They’re generally mild, worse at higher doses, and they usually settle within a few weeks. The rare but serious concerns are inflammation of the pancreas and gallstones, and nobody with a personal or family history of medullary thyroid cancer or MEN-2 should take these drugs at all.

Stomach side effects are what make or break the first two months. They’re worst while the dose is climbing and in the first weeks after each step up.

The patients who sail through tend to do the same handful of things. Start at the lowest dose, step up slowly (usually every four weeks), eat smaller portions, skip the heavy greasy meals early on, and drink enough water. A San Diego fish taco on week two of a dose increase is a bad idea, and I’ve heard about it from more than one patient. Most people who make it through the first eight weeks stay on the drug for years.

Low blood sugar is uncommon on its own. It becomes a real risk if you’re also taking insulin or one of the older sugar-lowering pills called sulfonylureas, and in that case those doses usually need to come down as the GLP-1 dose goes up, which is a coordination I’d rather handle with your endocrinologist or primary doctor before the first shot than after a bad afternoon.

Inflammation of the pancreas is rare. When researchers pooled the big studies, they didn’t find more cases of it or of pancreatic cancer than in the placebo groups. Even so, if I think someone might have it, I stop the drug, check a blood test called lipase, and reassess. I haven’t seen a reason to loosen that habit.

Gallstones run about 30% more common on these drugs, most likely because fast weight loss changes how the gallbladder empties. Most are ordinary stones that never cause trouble. An infected gallbladder is unusual.

Your resting heart rate goes up two to four beats a minute. Patients spot this on their watches and ask me about it more than almost anything else on this list. It hasn’t been tied to any problem.

SUSTAIN-6 raised a flag about eye damage from diabetes, called retinopathy, in people who’d had diabetes a long time and whose sugars dropped fast. That signal hasn’t shown up again in people without diabetes or in the kidney studies. If you’ve had poorly controlled diabetes for years, you and your eye doctor should be watching closely during the first few months on one of these.

Medullary thyroid cancer and the inherited gland syndrome MEN-2 are the two hard stops in the labeling. The warning came from rats, and human studies haven’t reproduced it. It’s still in the package insert and I still honor it.

You lose some muscle along with the fat. Lifting weights twice a week and eating enough protein, roughly 1 to 1.5 grams per kilogram of body weight a day, protect against that. I spend more clinic time on this than on any other part of the conversation, because dropping thirty pounds is only a win if it isn’t largely muscle, and the patients who do best long-term are the ones who started strength training the same month they started the shot.

One more. If your stomach already empties too slowly, a condition called gastroparesis, these drugs make it worse, and I steer around them when I know about it. Which means telling me you have it, since it rarely shows up on a medication list.

When Should You Start or Stop a GLP-1?

Start when you fit one of the groups above and you’re prepared for a weekly shot and a slow, stepwise dose increase. Pause it before a procedure that requires an empty stomach. Stop it for good if you develop pancreas inflammation, if the stomach side effects won’t quit, or if you become pregnant.

Before I add one, I want the rest of the plan already in place, meaning a statin, blood pressure handled with an ACE inhibitor or an ARB, and aspirin or a similar drug if it’s indicated. For diabetes, moderate doses usually do the job. For the heart benefit SELECT demonstrated, the target is semaglutide 2.4 mg weekly, and getting there takes several months of stepping up.

Because these drugs keep food in the stomach longer, the anesthesia societies now recommend holding them for a week before any procedure under general anesthesia. I bring this up at the time I write the referral rather than leaving it for the pre-op call, since I’ve watched a colonoscopy get cancelled the morning of over exactly this.

I don’t stop the drug when someone hits a goal weight. Weight comes back, and heart risk tracks right along with it. Two withdrawal studies confirmed this plainly, with most of the lost weight returning within a year of stopping. So I frame it the way I frame blood pressure medication. This is long-term management of a risk factor, not a course of antibiotics.

Cost is often the real obstacle. When it is, I work through which drug in the family your plan actually covers. Diabetes prescriptions are covered nearly everywhere. The weight-management versions, Wegovy and Zepbound, are hit or miss, and Medicare still doesn’t cover them for weight alone, though that keeps shifting. Manufacturer savings cards cut the out-of-pocket cost a lot if you have commercial insurance.

So Should You Take a GLP-1 Receptor Agonist?

If you have heart disease and a BMI of 27 or higher, or type 2 diabetes with high heart risk, or stiff-heart failure with obesity, the answer is probably yes. These are now part of standard heart prevention. Have the conversation with your cardiologist, who can weigh your own risk, your other conditions, and what you can actually get filled.

The shift has been fast. Five years ago semaglutide was a diabetes drug that happened to take weight off. Now it’s a heart drug that happens to help diabetes and weight, with evidence supporting it in people who don’t have diabetes at all.

Tirzepatide is walking the same path a few years behind.

In my Encinitas office the conversation runs about the same way each time. I go through your risk factors, your risk calculation, your coronary calcium score if we have one, where your weight has been heading, and what’s already on your medication list. If you fit one of the tiers, I lay out what the studies found, what the side effects feel like, how the pen works, and what it’s likely to cost you. Most people who fit choose to start. The ones who don’t are usually worried about needles, money, or nausea, and none of those are silly worries. They’re the right things to put on the other side of the scale.

Frequently Asked Questions About GLP-1 Receptor Agonists and the Heart

Are Ozempic and Wegovy the same drug?

Yes, both are semaglutide. Ozempic is the version approved for type 2 diabetes, going up to 2.0 mg weekly. Wegovy is the higher-dose version approved for weight management, going up to 2.4 mg weekly. Rybelsus is the daily pill. The heart data from SELECT used the 2.4 mg weight-management dose.

Does a GLP-1 work without weight loss?

Part of the heart benefit seems to happen regardless of the scale. SELECT found fewer heart attacks and strokes even among people whose weight barely moved, and laboratory work points to direct effects on blood vessels and inflammation. That said, most of the benefit does travel with weight loss, lower blood pressure, and better metabolic numbers, so people who tolerate the drug and lose real weight tend to get more out of it.

Can a GLP-1 cause muscle loss?

Some muscle goes along with any fast weight loss, these drugs included. Eating enough protein, roughly 1 to 1.5 grams per kilogram of body weight daily, and lifting weights twice a week protect against it. It’s a real issue and a manageable one, and the patients who do best long-term are the ones who train.

What is the difference between semaglutide and tirzepatide?

Semaglutide flips one gut-hormone switch. Tirzepatide flips two, adding a second hormone called GIP, and hitting both produces somewhat more weight loss (up to 22% in one study) and somewhat better blood sugar in head-to-head comparisons. Both have heart data. Semaglutide’s is deeper right now, and tirzepatide’s is still coming in.

Do GLP-1 drugs cause thyroid cancer?

Rat studies showed a signal for a rare thyroid cancer called medullary thyroid cancer, which is why the label warns against these drugs if you or a close relative has had it or has MEN-2 syndrome. Large human databases have not found more of this cancer in people taking them. The warning stands as a precaution, not a proven human risk.

Can you take a GLP-1 with a statin?

Yes. Most people taking a GLP-1 for heart reasons should be on a statin too. They work on completely different problems and there’s no meaningful interaction between them.

Are GLP-1 drugs covered by insurance?

For type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza), most commercial plans and Medicare Part D cover them. For weight management (Wegovy, Zepbound), coverage varies a lot, and Medicare still doesn’t cover them for weight alone. Manufacturer savings programs bring the cost down substantially if you have commercial insurance.

How long should you stay on a GLP-1?

For most people, indefinitely. The benefits last as long as the drug does. Two withdrawal studies showed that stopping brings the weight back and undoes the metabolic gains. A small number of people can come off after a big, durable improvement. Most should plan on staying, the way they’d plan on staying on a blood pressure pill.

References

1. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). New England Journal of Medicine. 2016;375(4):311-322.

2. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016;375(19):1834-1844.

3. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND). Lancet. 2019;394(10193):121-130.

4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232.

5. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine. 2024;391(2):109-121.

6. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). New England Journal of Medicine. 2023;389(12):1069-1084.

7. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes (STEP-HFpEF DM). New England Journal of Medicine. 2024;390(15):1394-1407.

8. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). New England Journal of Medicine. 2025;392(5):427-437.

9. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.

10. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.

11. American Diabetes Association Professional Practice Committee. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care. 2025.

12. Galli M, Benenati S, Laudani C, et al. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. Journal of the American College of Cardiology. 2025.